Ads
related to: sglt2 inhibitors drugs- See the FAQs
Get the Answers to Frequently
Asked Questions Today.
- View Patient Stories
Watch Videos of Patient Stories
Today to Start Your T1D Journey.
- View T1D Organizations
Stay Connected. Learn About
T1D Organizations Today.
- Join the Support Program
View Resources & Copay Assistance.
Terms & Conditions Apply.
- See the FAQs
Search results
Results From The WOW.Com Content Network
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.
They act by inhibiting sodium/glucose cotransporter 2 (SGLT-2), and are therefore also called SGLT-2 inhibitors. The efficacy of the drug is dependent on renal excretion and prevents glucose from going into blood circulation by promoting glucosuria. The mechanism of action is insulin independent.
The analysis showed that over a follow-up period of an average of 2.06 years for people on SGLT2 inhibitors, and 3.70 years for people on different antidiabetes drugs, there was a reduction in the ...
SGLT-2 inhibitors are a class of medications that treat type 2 diabetes. The medications help keep the kidneys from reabsorbing too much glucose and allow you to pee it out instead of circulating ...
SGLT2 is a member of the sodium glucose cotransporter family, which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. [6] SGLT2 is located in the early proximal tubule, and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney glomerulus. [7]